Active
SME

Goldline Pharmaceutical Ltd

Goldline Pharmaceutical Ltd IPO opened on 12 May 2026 and closed on 14 May 2026, with a price band of ₹41–₹43 per share. The IPO had a lot size of 3000 shares, requiring a minimum investment of ₹2,58,000 per lot at the upper price band. The issue size was ₹11.61 crore, and the shares get listed on 19 May 2026.

Goldline Pharmaceutical Ltd IPO Details

Listing Date

19 May 2026

Bid Price

₹41 - ₹43

Lot Size

3000 Shares

Minimum Investment

₹2,58,000 / 2 Lots

Issue Size

₹11.61 Cr

Key Dates to Track

    Here are the important dates you need to know in order to participate in this IPO

tick

Offer Start Date

12th May

tick

Offer End Date

14th May

tick

Allotment Date

15th May

tick

Refund Initiation

18th May

tick

Demat Transfer

18th May

tick

Listing Date

19th May

About Goldline Pharmaceutical Ltd IPO

Goldline Pharmaceuticals is engaged in the marketing and distribution of pharmaceutical products under the “Goldline” brand. The company’s portfolio is categorised into five divisions, namely Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness. These divisions cater to multiple therapeutic segments including cardiology, diabetology, orthopaedics, paediatrics, neurology, gastroenterology, critical care, and supportive cancer care. As per the company information, the portfolio consists of more than 140 products designed for different medical specialities and healthcare requirements. The company follows an asset-light operating model where medicines are manufactured through third-party manufacturing partners based on its product specifications and market requirements.
 

The company markets and distributes its products through a network of distributors supplying retailers and wholesalers across multiple states including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar. Goldline Pharmaceuticals currently works with 15 manufacturing partners and 7 distributors for its operations. In addition to product marketing, the company also supports hospitals and healthcare institutions with procurement and material supply services. Its business model is focused on product branding, distribution management, and therapeutic expansion across selected domestic markets while ensuring regulatory compliance and quality standards through third-party manufacturing arrangements.

Goldline Pharmaceutical Ltd Shareholding Pattern

  Pre-Issue Post-Issue
Promoter Group 79.7% 57.3%
Public Group 20.3% 42.7%

Goldline Pharmaceutical Ltd IPO Reservation

QIB Shares Offered 5,40,000 (20%)
NII (HNI) Shares Offered 3,90,000 (14.44%)
Retail Shares Offered 9,00,000 (33.33%)
Anchor Investor Shares Offered 7,32,000 (27.11%)
Total Shares Offered 27,00,000
Total Shares With Anchor Investor 27,00,000

Goldline Pharmaceutical Ltd IPO Lot Size

Application Lots Shares Amount
Retail (Min) 2 6,000 ₹2,58,000
Retail (Max) 2 6,000 ₹2,58,000
S HNI (Min) 3 9,000 ₹3,87,000
S HNI (Max) 7 21,000 ₹9,03,000
B HNI (MIN) 8 24,000 ₹10,32,000

Goldline Pharmaceutical Ltd IPO Anchor Portion Size

Bid Date May 11, 2026

Goldline Pharmaceutical Ltd IPO registrar

Bigshare Services Pvt Ltd
Phone Number +91 22 6263 8200
Email Id ipo@bigshareonline.com
Website www.bigshareonline.com

Goldline Pharmaceutical Ltd IPO Lead Manager

1. Cumulative Capital Private Limited

Goldline Pharmaceutical Ltd Financial Information

March 31, 2025 March 31, 2024 March 31, 2023
Net Worth ₹10.35 Cr ₹7.87 Cr ₹5.89 Cr
Reserves and Surplus ₹1.65 Cr ₹3.76 Cr ₹2.08 Cr
Total Borrowing ₹11.03 Cr ₹11.13 Cr ₹10.83 Cr

Goldline Pharmaceutical Ltd IPO Subscription LIVE Status

Category No. of shares offered No. of shares bid Subscription (Times)
Qualified Institutional Buyers (QIBs) 5,40,000 9,73,17,000 180.2167
Non Institutional Investors (NIIs) 5,28,000 64,83,33,000 1,227.9034
Retail Individual Investors (RIIs) 9,00,000 79,30,38,000 881.1533
Total 19,68,000 1,53,86,88,000 781.85

Strength of Goldline Pharmaceutical Ltd

  • Experienced promoters and management team with industry knowledge and a track record.
  • Asset-light business model and competitive products.
  • Scalable Business Model.
  • Wide and diverse range of product offerings.
  • Strong Supplier and Vendor Relationships.
  • Established Distribution Network.

Risks Involved

  • Its rely entirely on third-party contract manufacturers for the manufacturing of the company pharmaceutical products, and any failure or inability of such manufacturers to meet quality, regulatory, delivery or capacity requirements could adversely affect its business, results of operations and financial condition.
  • The Company has experienced delays in filing e-forms with the Registrar of Companies (RoC) in the past, resulting in the payment of late fees. Further, there have also been instances of erroneous filings made by the Company, in the past. While no regulatory actions or penalties has been imposed to date except below mentioned, there is no assurance that such actions will not be levied in the future. The Company cannot guarantee that similar delays will not occur in the future, and if regulatory authorities impose penalties or take punitive actions against the Company or its directors/officers, it could negatively affect the Company's business and financial condition.
  • The company commercial success is largely dependent upon its ability to analyses the market of new pharmaceutical products, failure of which may has an adverse impact on its revenue and profitability.
  • There has been instances of delays in payment of statutory dues, i.e. GST by the Company. In case of any delay in payment of statutory due in future by the Company, the Regulatory Authorities may impose monetary penalties on it or take certain punitive actions against the Company in relation to the same which may has adverse impact on its business, financial condition and results of operations.
  • Its depend on the company distributors for a significant portion of its revenue, and any decrease in revenues or sales from any one of the company key intermediaries may adversely affect its business and results of operations. the Company has a distribution network of 8 distributors and is dependent on these distributors for a significant portion of its revenue. If the company unable to maintain its relationship with such customers or if there is a reduction in their demand for the company products, its business, results of operations and financial condition will be materially and adversely affected.
  • There are outstanding mitigations involving the Company, Promoters, Directors, Key Managerial Personnel, Senior Management and Group Companies, if determined adversely, may adversely affect its business and financial condition.
  • The company Promoter Group entities Numerius Healthcare Private Limited, Nucleage Lifescience Private Limited and Nucleage Pharma Solutions Private Limited has conflicts of interest as they are engaged in similar business and may compete with it.
  • Its derive a significant portion of the company revenue from certain of its products. If sales volume or price of such products declines in the future, or if the company unable to sell such products for any reason, its business, financial condition, cash flows and results of operations could be adversely affected.
  • The company operate in limited geographies for a significant portion of its revenue and also depends on limited number of customers for the company revenue from operations.
  • The Company had negative cash flows in the past years, details of which are given below. Sustained negative cash flow could impact its growth and business.
stock
Invest in IPOs with ease

Sign-in to invest with your demat account, or set up a new demat account for free

Industry Outlook of Goldline Pharmaceutical IPO

  • The Indian pharmaceutical industry continues to witness growth supported by rising healthcare expenditure, increasing demand for generic medicines, and expansion in chronic disease treatment segments. India remains a major supplier of generic medicines to global markets, particularly regulated regions such as the US and Europe.

  • Growth in pharmaceutical distribution and marketing businesses is being supported by increasing penetration of healthcare services in semi-urban and rural regions, along with higher awareness regarding preventive healthcare and prescription-based treatments.

  • Asset-light pharmaceutical marketing models, where products are manufactured through third-party facilities, continue to be adopted by companies seeking operational scalability with lower capital expenditure requirements.

  • The sector is also witnessing increased focus on specialty therapies, chronic care medicines, and branded generics, supported by changing disease patterns and ageing demographics.

  • However, the industry continues to face challenges from fluctuations in raw material prices, supply chain disruptions, regulatory compliance requirements, and pricing controls on essential medicines.
     

Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your IPO allotment status for Goldline Pharmaceutical IPO.

Explore Other IPOs

  • Current IPOs
  • Upcoming IPOs
  • Closed IPOs
  • IPO Performance
  • All
  • MainBoard
  • SME
AVIENCE BIOMEDICALS LIMITED IPO
icon
Closing Today
SME IPO
Early Access
Bidding Period
18th Jun 2026 - 6th Jun 2026
Price Range
₹196.0 - 208.0
IPO Size
₹30,00,00,000
RIYAASAT LIFESTYLE LIMITED IPO
icon
Closing Today
SME IPO
Early Access
Bidding Period
18th Jun 2026 - 6th Jun 2026
Price Range
₹102.0 - 108.0
IPO Size
₹31,00,00,000
ANUBHAV PLAST LIMITED IPO
icon
Closing Tomorrow
SME IPO
Early Access
Bidding Period
19th Jun 2026 - 6th Jun 2026
Price Range
₹77.0 - 80.0
IPO Size
₹24,00,00,000
TURTLEMINT FINTECH SOLUTIONS LIMITED IPO
icon
Closing Tomorrow
SME IPO
Early Access
Bidding Period
19th Jun 2026 - 6th Jun 2026
Price Range
₹144.0 - 152.0
IPO Size
₹2,22,00,00,000
Bidding Period
23rd Jun 2026 - 6th Jun 2026
Price Range
₹769.0 - 808.0
IPO Size
₹6,15,00,00,000
ADVIT JEWELS LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
23rd Jun 2026 - 6th Jun 2026
Price Range
₹130.0 - 138.0
IPO Size
₹1,65,00,00,000
SHREEDHAR SPINNERS LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
23rd Jun 2026 - 6th Jun 2026
Price Range
₹51.0 - 53.0
IPO Size
₹31,00,00,000
  • All
  • MainBoard
  • SME
Jivial Industries Limited IPO
icon
SME IPO
Early Access
Bidding Period
23rd Jun 2026 - 6th Jun 2026
Price Range
₹196.0 - 196.0
IPO Size
₹31,99,00,000
CSM Technologies Limited IPO
icon
SME IPO
Early Access
Bidding Period
24th Jun 2026 - 6th Jun 2026
Price Range
₹107.0 - 113.0
IPO Size
₹1,45,78,00,000
Dhanwel Hybrid Seeds Limited IPO
icon
SME IPO
Early Access
Bidding Period
24th Jun 2026 - 6th Jun 2026
Price Range
₹95.0 - 99.0
IPO Size
₹26,73,00,000
Bidding Period
24th Jun 2026 - 6th Jun 2026
Price Range
₹207.0 - 212.0
IPO Size
₹94,51,00,000
Crazy Snacks Limited IPO
icon
SME IPO
Early Access
Bidding Period
25th Jun 2026 - 6th Jun 2026
Price Range
₹39.0 - 42.0
IPO Size
₹31,47,00,000
Bidding Period
25th Jun 2026 - 6th Jun 2026
Price Range
₹94.0 - 99.0
IPO Size
₹47,91,00,000
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aastha Spintex Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
AceVector Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advanced SysTek Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advanta Enterprises Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Agilus Diagnostics Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Airox Technologies Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Ajay Poly Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allchem Lifescience Limited IPO
icon
SME IPO
Early Access
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
NO ACTIVE IPO HERE
  • All
  • MainBoard
  • SME
CLAY CRAFT INDIA LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
17th Jun 2026 - 6th Jun 2026
Price Range
₹193.0 - 203.0
IPO Size
₹1,10,00,00,000
DIKSHA POLYMERS LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
17th Jun 2026 - 6th Jun 2026
Price Range
₹112.0 - 112.0
IPO Size
₹18,00,00,000
Bidding Period
17th Jun 2026 - 6th Jun 2026
Price Range
₹21.0 - 23.0
IPO Size
₹89,00,00,000
LIOTECH INDUSTRIES LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
17th Jun 2026 - 6th Jun 2026
Price Range
₹321.0 - 321.0
IPO Size
₹36,00,00,000
Bidding Period
12th Jun 2026 - 6th Jun 2026
Price Range
₹98.0 - 103.0
IPO Size
₹54,00,00,000
Bidding Period
11th Jun 2026 - 6th Jun 2026
Price Range
₹120.0 - 127.0
IPO Size
₹70,00,00,000
Bidding Period
10th Jun 2026 - 6th Jun 2026
Price Range
₹62.0 - 66.0
IPO Size
₹35,00,00,000
HEXAGON NUTRITION LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
5th Jun 2026 - 6th Jun 2026
Price Range
₹42.0 - 45.0
IPO Size
₹1,39,00,00,000
GENXAI ANALYTICS LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
5th Jun 2026 - 6th Jun 2026
Price Range
₹110.0 - 116.0
IPO Size
₹54,84,00,000
VAHH CHEMICALS LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
4th Jun 2026 - 6th Jun 2026
Price Range
₹61.0 - 61.0
IPO Size
₹13,00,00,000
UHM VACATION LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
4th Jun 2026 - 6th Jun 2026
Price Range
₹157.0 - 166.0
IPO Size
₹36,02,00,000
Bidding Period
3rd Jun 2026 - 6th Jun 2026
Price Range
₹182.0 - 192.0
IPO Size
₹6,31,00,00,000
MERRITRONIX LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
1st Jun 2026 - 6th Jun 2026
Price Range
₹141.0 - 149.0
IPO Size
₹70,00,00,000
SMR JEWELS LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
26th May 2026 - 6th Jun 2026
Price Range
₹125.0 - 128.0
IPO Size
₹12,54,00,000
AUREATE TRADDE LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
29th May 2026 - 6th Jun 2026
Price Range
₹70.0 - 70.0
IPO Size
₹27,00,00,000
Bidding Period
26th May 2026 - 5th May 2026
Price Range
₹59.0 - 63.0
IPO Size
₹18,00,00,000
HARIKANTA OVERSEAS LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
20th May 2026 - 5th May 2026
Price Range
₹86.0 - 91.0
IPO Size
₹24,00,00,000
YAASHVI JEWELLERS LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
25th May 2026 - 5th May 2026
Price Range
₹83.0 - 83.0
IPO Size
₹44,00,00,000
M R MANIVENI FOODS LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
22nd May 2026 - 5th May 2026
Price Range
₹51.0 - 52.0
IPO Size
₹27,00,00,000
QLINE BIOTECH LIMITED IPO
icon
SME IPO
Early Access
Bidding Period
21st May 2026 - 5th May 2026
Price Range
₹326.0 - 343.0
IPO Size
₹2,14,00,00,000
  • All
  • MainBoard
  • SME
Issue Prize
103.00
Listing Day Close
147.30(42.72%)
Issue Prize
127.00
Listing Day Close
195.30(53.54%)
Issue Prize
66.00
Listing Day Close
62.70(-4.55%)
HEXAGON NUTRITION LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
45.00
Listing Day Close
50.39(11.11%)
GENXAI ANALYTICS LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
116.00
Listing Day Close
97.40(-16.38%)
VAHH CHEMICALS LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
60.00
Listing Day Close
66.50(11.67%)
UHM VACATION LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
166.00
Listing Day Close
126.20(-24.10%)
Issue Prize
192.00
Listing Day Close
247.90(29.17%)
MERRITRONIX LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
149.00
Listing Day Close
297.25(99.33%)
SMR JEWELS LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
128.00
Listing Day Close
103.05(-19.53%)
AUREATE TRADDE LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
70.00
Listing Day Close
66.50(-4.29%)
Issue Prize
63.00
Listing Day Close
60.57(-3.17%)
HARIKANTA OVERSEAS LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
91.00
Listing Day Close
75.77(-16.48%)
YAASHVI JEWELLERS LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
83.00
Listing Day Close
87.05(4.82%)
M R MANIVENI FOODS LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
52.00
Listing Day Close
41.13(-21.15%)
QLINE BIOTECH LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
343.00
Listing Day Close
474.60(38.48%)
AUTOFURNISH LIMITED IPO
icon
SME IPO
Early Access
Issue Prize
41.00
Listing Day Close
45.15(9.76%)
Issue Prize
139.00
Listing Day Close
115.80(-16.55%)
Issue Prize
77.00
Listing Day Close
124.00(61.04%)
Issue Prize
63.00
Listing Day Close
72.75(15.87%)

Frequently Asked Questions

What is Goldline Pharmaceutical Ltd IPO?

Answer Field

Goldline Pharmaceutical Ltd IPO is a SME IPO of 27,00,000 equity shares of a face value of ₹10 aggregating up to ₹11.61 Crores. The issue is priced at ₹41 to ₹43 per share. The minimum order quantity is 3000 Shares. The IPO opens on May 12, 2026, and closes on May 14, 2026. Bigshare Services Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE-SME.

When Goldline Pharmaceutical Ltd IPO will open?

Answer Field

The Goldline Pharmaceutical Ltd IPO opens on May 12, 2026 and closes on May 14, 2026.

What is the lot size of Goldline Pharmaceutical Ltd?

Answer Field

Goldline Pharmaceutical Ltd lot size is 3000 shares, and the minimum amount required is ₹2,58,000.

How to apply for Goldline Pharmaceutical Ltd IPO?

Answer Field

You can apply in Goldline Pharmaceutical Ltd IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

  • Login to Bajaj Broking account App/Website & click on IPO
  • Enter the number of lots and price at which you wish to apply.
  • Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
  • You will receive a mandate notification to block funds in your UPI app.
  • Approve the mandate request on your UPI and funds will be blocked.

When is Goldline Pharmaceutical Ltd IPO allotment?

Answer Field

The finalization of Basis of Allotment for Goldline Pharmaceutical Ltd IPO will be done on May 15, 2026, and the allotted shares will be credited to your demat account by May 18, 2026.

When is Goldline Pharmaceutical Ltd IPO listing date?

Answer Field

The Goldline Pharmaceutical Ltd listing date is May 19, 2026.

Who is the registrar of Goldline Pharmaceutical Ltd IPO?

Answer Field

The registrar of Goldline Pharmaceutical Ltd IPO is Bigshare Services Pvt Ltd

Which company is the book-running lead manager of the IPO?

Answer Field

Cumulative Capital Private Limited will be the book-running lead manager of this IPO.

What is the fresh issue of Goldline Pharmaceutical Ltd IPO?

Answer Field

The fresh issue size is ₹11.61 Crores equity shares.

What minimum lot size can retail subscribers subscribe to Goldline Pharmaceutical Ltd?

Answer Field

Retail investors can subscribe to a minimum of one lot, 3000 shares and ₹2,58,000 amount.

How can I approve the UPI mandate request for Goldline Pharmaceutical Ltd IPO?

Answer Field

To apply for Goldline Pharmaceutical Ltd IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

What is the price range of Goldline Pharmaceutical Ltd?

Answer Field

The price of each Goldline Pharmaceutical Ltd share will be ranging in between ₹41 to ₹43 per share.

What is the cut-off time for the UPI mandate for Goldline Pharmaceutical Ltd IPO?

Answer Field

The cut-off time for the UPI mandate confirmation is 5:00 PM, May 14, 2026.

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|